Abstract | The specialized cytokine secretion profiles of T helper (T H ) cells are the basis for a focused and efficient immune response. On the twentieth anniversary of the first descriptions of the cytokine signals that promote the differentiation of interleukin-9 (IL-9)-secreting T cells, this Review focuses on the extracellular signals and the transcription factors that promote the development of what we now term T H 9 cells, which are characterized by the production of this cytokine. We summarize our current understanding of the contribution of T H 9 cells to both effective immunity and immunopathological disease, and we propose that T H 9 cells could be targeted for the treatment of allergic and autoimmune disease.
T helper (T H ) cell subsets differentiate from CD4
+ T cells that have been exposed to a specialized cytokine environment
. Compared with the other T H cell subsets that have been described, T H 9 cells (which are defined by their secretion of interleukin-9 (IL-9)) are less well characterized, and it is only recently that we have begun to understand the factors that control their development and function. Schmitt et al. 1,2 first described IL-9 production by activated mouse T cells and subsequently defined the cytokines that promote the differentiation of IL-9-producing T H cells in culture. IL-9-producing T cells were first thought to be associated with T H 2-type responses in vivo and, because initial surveys of IL-9 function suggested that this cytokine had restricted effects during immune responses, it was not as extensively studied as many other cytokines that are associated with T H cells [3] [4] [5] . Moreover, the lack of understanding of how to derive highly polarized T H cells that produce IL-9 has hampered further investigation of the molecular control of Il9 gene expression.
The initial description of polarized IL-9-secreting T H cells was made from experiments in which T cells were cultured in the presence of IL-2, IL-4 and transforming growth factor-β (TGFβ) 1 . Although IL-4 stimulation of T cells alone was not sufficient to induce IL-9 production, it primed the cells to produce IL-9 when they were stimulated with additional cytokines. Veldhoen et al. 6 revisited this paradigm by showing that fully differentiated IL-4-producing T H 2 cells that are cultured in the presence of TGFβ subsequently produce IL-9. Dardalhon et al. 7 found that the same combination of cytokines can prime IL-9 production by T cells, and they showed that IL-4-mediated signalling promoted T H 9 cell differentiation partly by suppressing the ability of TGFβ to induce the expression of the regulatory T (T Reg ) cell-associated transcription factor forkhead box P3 (FOXP3). Thus, the balance of signals induced by these stimuli determines the extent of T H 9 cell generation.
In this Review, we integrate our current understanding of the factors that control the development and function of T H 9 cells with the role of T H 9 cells in immune responses and disease. We focus on some of the more recent functions described for T H 9 cells in atopic disease and inflammatory bowel disease, and in promoting effective antitumour immunity.
Regulation of T H 9 cell development
Downstream of the T cell receptor (TCR), costimulatory (FIG. 2; TABLE 1 ) and cytokine receptor signalling (TABLE 2) that promote T H 9 cell differentiation is a network of transcription factors that regulate the expression of T H 9 cell signature genes, including IL9 (FIG. 2) . In contrast to the co-stimulatory signals and the cytokines that induce the transient activation of transcription factors such as nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT) to acutely stimulate IL-9 production, cytokines including IL-4 and TGFβ regulate multiple genes in T H 9 cells, which leads to the generation of an Il9 locus that is poised to be activated in response to subsequent stimulation (BOX 2) . This section of the Review focuses on how cytokine-induced signals regulate T H 9 cell generation, including through the activation of signal transducer and activator of transcription (STAT) proteins, which is a first step in T H cell subset differentiation
, and through the TGFβ-induced activation of SMAD proteins, which can alter the outcome of STAT signalling in T H 9 cell differentiation.
STAT6 in T H 9 cell development. STAT6 is the major signalling component of the IL-4 receptor (IL-4R
) and is required for the in vitro generation of T H 9 cells [6] [7] [8] . Although STAT6 might directly bind to the Il9 locus 8, 9 , it is clear that STAT6 may have a more important role in controlling the T H 9 cell phenotype. STAT6 suppresses TGFβ-induced FOXP3 expression and the expression of the T H 1 cell-associated transcription factor T-bet (also known as TBX21), both of which repress IL-9 production [6] [7] [8] . IL-4 and STAT6 also have a crucial role in the induction of the T H 9 cell developmental programme. Recent work defined a T H 9-specific gene signature that distinguishes T H 9 cells from their closely related T H 2 cell and in vitro-derived T Reg (iT Reg ) cell counterparts. Interestingly, the majority of the genes that were enriched in T H 9 cells were STAT6 dependent 10 , including the genes encoding the transcription factors interferon-regulatory factor 4 (IRF4) and basic leucine zipper transcription factor ATF-like (BATF).
IRF4 expression is crucial for T H 9 cell differentiation, in addition to its previously documented requirement for the differentiation of T H 2 cells and T H 17 cells [11] [12] [13] . IL-9-secreting T cells were decreased in T H 9 cell cultures that were derived from naive IRF4-deficient T cells or from cells that were treated with Irf4-specific short interfering RNA (siRNA) 13 . Moreover, ectopic expression of IRF4 increases IL-9 production in T H 9 cell cultures 10 . IRF4 directly bound to the Il9 promoter and increased Il9 transcription in a reporter assay, which suggests that IRF4 has a major role in directly inducing transcription of the Il9 gene in T H 9 cells 10, 13 . Despite its requirement for Il9 expression, IRF4 only regulates a subset of other T H 9 cell-associated genes 10 . Interestingly, deletion of STAT6 or IRF4 from T cells results in increased expression of T-bet and interferon-γ (IFNγ), which suppress T H 9 cell development 10, 13 . Therefore, it is likely that IRF4 supports T H 9 cell development by directly inducing Il9 transcription as well as by blocking the expression of T H 1 cell-associated transcription factors that may inhibit T H 9 cell differentiation.
In addition to IRF4, BATF is required for T H 9 cell development 10 and this parallels a similar requirement seen in the generation of T H 17 cells 14 , in which BATF and IRF4 work as a transcriptional module [15] [16] [17] . Naive CD4 + T cells isolated from mice lacking BATF show a marked impairment in T H 9 cell differentiation, and naive CD4 + T cells in which BATF was ectopically expressed or T cells from Batf-transgenic animals show an enhanced propensity to produce IL-9 when cultured under T H 9 cell-inducing conditions 10 . Similarly to IRF4, BATF was shown to bind to the Il9 promoter and to activate Il9 transcription in reporter assays 10 . However, in contrast to IRF4, which regulates a fairly small number of T H 9 cell-associated genes, BATF deficiency resulted in a marked defect in the expression of nearly all of the T H 9 cell-associated genes that were examined, which mirrored observations in STAT6-deficient T cells 10 . The difference between the effects of BATF and IRF4 in altering the overall scope of the T H 9 cell-specific gene signature highlights that although BATF and IRF4 can function as a transcriptional module [15] [16] [17] , it is likely that BATF and IRF4 also provide unique contributions to establishing the T H 9 cell phenotype.
Although GATA-binding protein 3 (GATA3) expression is lower in T H 9 cells than in T H 2 cells 6, 8 , it is an important STAT6 target gene that is involved in T H 9 cell differentiation. Dardalhon et al. 7 showed that GATA3-null cells failed to produce IL-9 when cultured under T H 9 cell-skewing conditions and that this was concomitant with increased FOXP3 expression linked to a possible physical interaction between the GATA3 and FOXP3 proteins. However, the function of GATA3 in T H 9 cell differentiation remains unclear as some studies detected little Gata3 mRNA in T H 9 cells compared with in T H 2 cells, and ectopic expression of GATA3 in T H 9 cells increased IL-9 production in some studies but not in others 6, 8, 18 . The differing results in these studies may reflect the amount of GATA3 within the cell. Despite GATA3 expression in all T cells, induced expression of GATA3 might repress FOXP3 induction without activating T H 2 cell-associated genes. In higher amounts, GATA3 might activate the expression of T H 2 cell-associated genes and might repress the ability of PU.1 (a T H 9 cell-inducing factor discussed below) to activate Il9 . Thus, a gradient of GATA3 expression might be instrumental in establishing the identity of multiple T H cell subsets.
STAT5
in T H 9 cell development. STAT5 affects the development of T H 9 cells downstream of several extracellular factors. IL-2 activates STAT5 in T cells and promotes the development of T H 9 cells. IL-2-deficient CD4 + T cells show a complete loss of IL-9-secreting cells in vitro 1 , a finding that was revisited 20 years after its discovery 22 . In both reports, the addition of exogenous IL-2 rescued IL-9 production in IL-2-deficient T cells
Box 1 | STAT proteins and T H cell subsets
The differentiation of CD4 + T cells into T helper (T H ) cells is initiated when naive CD4 + T cells are stimulated by antigen in the context of MHC class II molecules and acquire the ability to respond to a cytokine environment that promotes the development of specialized effector cell phenotypes. The specialized or polarized effector cell subset, termed a T H cell subset, is identified by the production of signature cytokines and expresses a characteristic transcriptional signature. Polarized T H subsets mainly develop in response to a specific cytokine environment, although activation signal strength and non-cytokine signals also affect differentiation. The cytokine environment activates signal transducer and activator of transcription (STAT) family members, which induce the expression of lineage-specific genes, modify local chromatin architecture and establish a genome-wide enhancer profile [105] [106] [107] [108] [109] [110] . Among the genes activated by STAT proteins are cytokines that confer specific functions to the T H cell subset; chemokine receptors and adhesion molecules that allow the T cell to migrate into sites of inflammation; and additional transcription factors that function to further establish and maintain the characteristic pattern of gene expression. STAT proteins, although transiently activated, are gateways to the process of T H cell differentiation and the first step on the road to commitment to a specific T H cell phenotype.
that were cultured in the presence of TGFβ alone or with IL-4 (REFS 1, 22) . The role of STAT5 in IL-9 production was directly shown by studies in which its deletion in cultured T H 9 cells resulted in a dramatic decrease in IL-9 production 1, 22 . These findings were corroborated by the use of STAT5 inhibitors and Stat5-targeting siRNAs to block IL-9 production in naive CD4 + T cells cultured under T H 9 cell-skewing conditions 23 . These studies showed significant STAT5 binding within the Il9 promoter using chromatin immunoprecipitation and showed that constitutively active STAT5 could directly activate the Il9 promoter in reporter assays. In addition to direct effects on Il9, STAT5 probably affects other components of T H 9 cell differentiation. Blockade of IL-2 or inhibition of STAT5 resulted in a decrease in the expression of IRF4 and PU.1, both of which are transcription factors that are required for T H 9 cell differentiation 10, 13, 20 . Furthermore, the IL-2-STAT5 signalling pathway is closely linked with cellular proliferation and metabolism, which are processes that also affect T H cell differentiation, and approaches to distinguish direct and indirect effects of this pathway will be complex.
Although IL-2 is probably a primary activator of STAT5 in T cells, thymic stromal lympho poietin (TSLP) also promotes IL-9 production by cells cultured under T H 9 cell-inducing, but not T H 2 cellinducing, conditions 24 . T H 9 cells express the TSLP receptor, which is upregulated after TSLP stimulation 24 . TSLP also augmented levels of phosphorylated STAT5 throughout the course of T H 9 cell differentiation and resulted in increased STAT5 binding to the Il9 locus 24 . Importantly, inhibition of STAT5 via siRNA abrogated the capacity of TSLP to increase IL-9 production by T H 9 cells 24 . Interestingly, TSLP was still capable of augmenting IL-9 production when IL-2 was blocked using monoclonal antibodies in these cultures. These data suggest that IL-2 and TSLP may work together to promote IL-9 production in T cells, particularly in vivo, and that TSLP might substitute for IL-2 under some conditions.
There are additional factors that also induce IL-9 production by increasing IL-2 production. The tumour necrosis factor (TNF) superfamily member TNF ligand-related molecule 1A (TL1A; also known as TNFSF15) was shown to enhance IL-9 production independently of STAT6 and PU.1, which are important for in vitro and in vivo T H 9 cell generation 25 . Ligation of the TL1A receptor, death receptor 3 (DR3; also known as TNFRSF25), resulted in enhanced IL-2 production and STAT5 activation, which was required for the induction of IL-9 (REF. 25 ). Nitric oxide also functions by increasing endogenous IL-2 production and STAT5 activation 26 . Thus, in some environments, TL1A or nitric oxide might enhance IL-9 production by activating the IL-2-STAT5 pathway.
STAT5 also has broad effects in T H 9 cell programming. Studies found that blockade of IL-2 or inhibition of STAT5 resulted in an increase in the mRNA and protein expression of the transcriptional repressor B cell lymphoma 6 (BCL-6). BCL-6 was originally identified as a proto-oncogene in B cell lymphomas and was later shown to be a primary transcriptional regulator in CD4 + T follicular helper (T FH ) cells 27, 28 . T H 9 cells show lower levels of Bcl6 expression than other in vitro-generated T H cells, and Bcl6 expression inversely correlates with Il9 and Il2 mRNA levels in T H 9 cells 22, 23 . Moreover, retrovirus-mediated expression of BCL-6 in T H 9 cells was shown to inhibit both T H 9 cell differentiation and IL-2-induced Il9 transcription, although only one report showed increased IL-9 production from T cells that had diminished BCL-6 expression 22, 23 . However, both studies showed that BCL-6 bound the Il9 promoter at overlapping or adjacent regions to STAT5 and repressed the ability of STAT5 to promote Il9 transcription in reporter assays 22, 23 . These data suggest a molecular circuit in which early IL-2 production activates STAT5 binding to the Il9 promoter, which outcompetes BCL-6 binding to the promoter, and represses Bcl6 expression. As IL-2 exposure and STAT5 activation wane, the STAT5-mediated suppression of BCL-6 activity diminishes and BCL-6 has better access the Il9 promoter, which subsequently limits IL-9 production. In an asthma model, deficiency in non-receptor tyrosine protein kinase 2 (TYK2), the Janus kinase that is required for type I IFN signalling and STAT1 activation, resulted in increased IL-9 production 29 . In an experimental autoimmune encephalomyelitis (EAE) model system, IFNγ induced IL-27 production by dendritic cells (DCs), which suppressed T H 9 cell differentiation both in vivo and in vitro in a STAT1-dependent and T-bet-dependent manner 30 . Although treatment of T H 9 cells with IL-27 induced the production of IFNγ and IL-10, which are cytokines that suppress T H 9 cell differentiation, the inhibition of IL-9 production by IL-27 was independent of these cytokines 30 . Further work must be carried out in order to understand how STAT1 functions downstream of IFNγ and IL-27 to suppress IL-9 production in T H 9 cells. Nature Reviews | Immunology In contrast to the inhibitory effect of STAT1 on T H 9 cell differentiation following IFNγ or IL-27 exposure, other reports suggest that a distinct subset of STAT1-activating cytokines may promote IL-9 production in T cells. Naive human CD4
+ T cells that were cultured under T H 9 cellinducing conditions with the STAT1-activating cytokines IFNα, IFNβ, IL-6 or IL-21 showed a marked increase in their capacity to produce IL-9 (REF. 31 ). Similarly, the treatment of mouse T H 9 cell cultures with IL-1β resulted in the indirect activation of STAT1, which induced expression of IRF1 (REF. 32); IRF1 subsequently bound to the Il9 promoter and, in combination with IRF4 and PU.1, directly enhanced Il9 transcription in a reporter assay. It has also been shown that IL-21 can have either positive or negative effects on IL-9 production depending on the culture conditions 22, 31, 32 . Thus, the effects of STAT1-activating cytokines on T H 9 cell development are complex and are controlled by additional cytokine signals that are present in the environment.
TGFβ and SMAD signalling in T H 9 cell development.
Studies have shown that TGFβ can 'reprogramme' T H 2 cells into IL-9-secreting T H 9 cells 6, 7 . Although still being defined in T H 9 cells, both SMAD-dependent and SMAD-independent pathways are required for T Reg cell and T H 17 cell differentiation [33] [34] [35] . Wang et al. 36 and Tamiya et al. 18 showed that SMAD2, SMAD3 and SMAD4 are required for optimal T H 9 cell differentiation. Deficiency of SMAD2 or SMAD4 in T cells has been shown to result in increased expression of the genes encoding T H 2 cell-associated cytokines and in a loss of IL-9 expression 36 . SMAD2 and SMAD3 bind to multiple conserved non-coding regions within the Il9 promoter 18 , and SMAD2, SMAD3 and SMAD4 have also been shown to alter the chromatin structure of the Il9 locus. However, these reports described distinct mechanisms for SMAD activity. Wang et al. 36 observed an increase in repressive histone marks in the Il9 promoter in the absence of either SMAD2 or SMAD4, as a result of enhanced Polycomb protein (enhancer of zeste homologue 2 (EZH2)) recruitment to the Il9 promoter. By contrast, Tamiya et al. 18 showed a loss of permissive histone marks in the absence of SMAD2 and SMAD3, and showed no change in repressive marks. Interestingly, the SMAD pathway might also provide a link to other T H 9 cell-inducing pathways.
Notch proteins were required for the binding of SMAD3 to the Il9 gene 37 . Moreover, SMAD2 or SMAD3 can form a physical complex with IRF4, and IRF4 and SMADs were reciprocally required for optimal binding to the Il9 promoter. IRF4 was also required for SMAD-mediated Il9 transcription in a reporter assay 18 . These data provide the groundwork for a model that could be used to explain how the IL-4-STAT6-induced activation of IRF4 and the TGFβ-driven activation of SMADs work together to transactivate the Il9 gene.
PU.1 is an ETS family transcription factor that is also induced by TGFβ in conjunction with antigen receptor stimulation and it is crucial for T H 9 cell differentiation 8, [19] [20] [21] 38 . PU.1-deficient CD4 + T cells have a diminished capacity to produce IL-9 and an increased propensity to produce T H 2 cell-related cytokines, whereas ectopic PU.1 expression in either T H 2 cells or T H 9 cells increases IL-9 production 20 . Therefore, PU.1 is so far the only transcription factor that induces IL-9 production in other T H cell subsets. Similarly to the other factors described above, PU.1 binds to the Il9 promoter and probably enhances gene transcription by recruiting histone acetyltransferases (HATs) and by promoting permissive chromatin structure 20, 38 . Interestingly, PU.1 is one of the few genes that is not induced by IL-4-STAT6 signalling in T H 9 cells, but is instead induced downstream of TGFβ signalling 8, 10 . Studies that compared SMADdeficient and wild-type T cells that were cultured under T H 9 cell-inducing conditions failed to observe differential expression of the PU.1-encoding Sfpi1 gene, which suggests that PU.1 may be regulated by SMAD-independent TGFβ-induced signalling mechanisms.
In summary, the development of T H 9 cells involves the coordinated function of key transcription factors downstream of IL-4-STAT6 and IL-2-STAT5 signalling, including IRF4 and BATF. In addition, TGFβ-induced SMAD proteins and the SMAD-independent induction of PU.1 are required to generate IL-9-secreting T cells. These pathways converge in the ability of IRF4 to interact with BATF and SMAD proteins. How these factors contribute to the stability of the T H 9 phenotype is still unclear
. The outcome of the activity of these transcription factors in relation to T H cell function is discussed in the sections below, focusing on the role of T H 9 cells in inflammatory disease and immunity. 41BBL, 41BB ligand; APC, antigen-presenting cell; DLL, Delta-like ligand; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor-κB; NICD1, Notch 1 intracellular domain; OX40L, OX40 ligand; PD1, programmed cell death protein 1; PDL2, programmed cell death 1 ligand 2; PI3K, phosphoinositide 3-kinase; TCR, T cell receptor; T H 9, T helper 9; TRAF, TNF receptor-associated factor; SHP2, SRC homology 2 domain-containing protein tyrosine phosphatase 2 (also known as PTPN11).
T H 9 cells in immunity and disease As IL-9 is a pleiotropic cytokine
, T H 9 cells might contribute to both protective immunity and immunopathological disease through a myriad of pathways. However, it is important to remember that T H 9 cells are not the only source of IL-9 during an immune response and, accordingly, the relative importance of T H 9 cells
in vivo has been difficult to define. In the remainder of this Review, we discuss our current understanding of T H 9 cell immune activity in specific diseases using data from human patients. We also describe the complementary experimental research in mouse models of disease that supports the idea that T H 9 cell-mediated inflammation has a role in human diseases (FIG. 3) . [39] [40] [41] [42] [43] [44] [45] . Patients with allergy have higher numbers of circulating T cells that are capable of producing IL-9 in response to pollen, cat dander, peanuts and house dust mite (HDM) extract than control individuals 39, [46] [47] [48] [49] [50] , and DCs isolated from these patients were more likely to stimulate IL-9 production from T cells 51 . Furthermore, IL-9-producing T cells from patients with atopy expressed the T H 9 cell-related proteins IL-17RB, IRF4 and PU.1 but did not express the T H 2-type cytokine IL-5 (REFS 39,51) (TABLE 2). The number of T H 9 cells and the serum levels of IL-9 in individuals with atopy directly correlated with allergen-specific IgE titres 24, 46, 47, 49 . In addition, T H 9 cell numbers and T cell IL-9 production were significantly increased with respect to control individuals in children with atopy 20, 49 and in patients with atopic dermatitis and psoriasis 48 . In mouse models of asthma (in which HDM extract, Aspergillus fumigatus or ovalbumin (OVA) are used as sensitizers), T H 9 cells are detectable in the respiratory tract and in the draining lymph nodes, particularly during the early stages of the disease 47, 52, 53 . In the OVA sensitization model, T H 9 cells are a main in vivo source of IL-9 during allergic airway disease, as determined by an IL-9 fate reporter mouse 54 . T H 9 cells and IL-9 levels in these models are increased when the pro-allergic cytokines IL-25 and TSLP (TABLE 2) are ectopically or exogenously expressed, and IL-9 is inhibited by the activity of cyclooxygenase 2, which may decrease IL-25R expression 24, 55, 56 . Furthermore, inhibiting T H 9 cell differentiation in vivo by neutralizing TGFβ or activin A -which is a TGFβ family member that also induces T H 9 cell differentiation -impairs development of allergic disease 47 . Moreover, inflammation is attenuated in mice with conditional deficiencies in PU.1 and IRF4 or in mice with germ line deficiencies in BATF 10, 13, 18, 20, 24, 47, 57, 58 . Importantly, PU.1-deficient mice, which have more specific defects in T H 9 cell development, have normal T H 2 cell responses but still do not develop severe inflammation in an OVA sensitization model 20 . Mouse models of atopic disease indicate that T H 9 cells mediate disease through the production of IL-9. The adoptive transfer of T H 9 cells promotes mast cell and eosinophil accumulation, mucus production, T H 2-type cytokine production and bronchial hyperresponsiveness 10, 13, 24, 26, 59 ; however, these effects are negated following transfer of Il9 −/− T H 9 cells or following IL-9 neutralization 10, 13, 24, 26 . Furthermore, adoptive transfer of T H 9 cells promotes greater mast cell accumulation than the transfer of T H 2 cells, and this is dependent on IL-9 but not on IL-13 (REF. 58 ).
In an HDM-induced asthma model that requires an endogenous T cell response, IL-9 neutralization or PU.1 deficiency within the T cell compartment significantly reduces mucus hyperplasia, mast cell accumulation, lung remodelling and airway hyperreactivity 58, 60 . IL-9 stimulates mast cell proliferation and activity in vivo [61] [62] [63] and can promote cytokine production by type 2 innate lymphoid cells (ILC2s) 54, 64 . Furthermore, transgenic expression of IL-9 is sufficient in itself to cause bronchial hyperresponsiveness via its effects on the respiratory epithelium and the enhancement of T H 2-type cytokine release [65] [66] [67] . Collectively, these models indicate that, although other cells can produce IL-9, T H 9 cells are crucial in a diverse set of Box 2 | Distinguishing acute expression of a cytokine and commitment to a T H cell subset T helper (T H ) cell subsets are often identified solely by the expression of a hallmark cytokine, which is typically assessed following stimulation of the cell with T cell receptor ligation or surrogate pharmacological activators, such as phorbol myristate acetate (PMA) and ionomycin. This stimulation results in acute activation of a particular cytokine locus (or loci) that is programmed or poised to be expressed upon stimulation. Among the factors activated by these pathways are nuclear factor of activated T cells (NFAT) and nuclear factor-κB (NF-κB) family members that, in the case of T H 9 cells, can bind directly to the interleukin-9 (Il9) locus (FIG. 2; TABLES 1,2) . In addition to T cell receptor ligation, several other ligands can induce IL-9 production through mechanisms that have been proven to, or that are likely to, require NF-κB family members, including OX40 and other tumour necrosis factor (TNF) superfamily members, IL-1 and related family members, and IL-25 (see details and references in TABLE 2) . The details of NF-κB family members in these IL-9 co-stimulatory pathways have recently been reviewed 111 .
The effects of the ligands that acutely induce IL-9 production are probably distinct from those responsible for the programming of the Il9 locus, which requires many of the transcription factors described in detail in this Review, including signal transducer and activator of transcription 5 (STAT5), STAT6, PU.1, basic leucine zipper transcriptional factor ATF-like (BATF), interferon-regulatory factor 4 (IRF4) and SMAD proteins. These subset-promoting transcription factors induce genes other than Il9 and initiate changes in chromatin structure that are characteristic of differentiated cells. However, it has been difficult to examine the commitment of T cells to the IL-9-secreting phenotype because the T H 9 cell phenotype seems to be transient in vitro and in some autoimmune disease models 78, 82 . Despite these observations, IL-9-producing T cells have been identified in both healthy and diseased human skin 48, 90 , and in several mouse models of disease 61, 69 . Moreover, IL-9 + T cells that are negative for other cytokines (including IL-13 and interferon-γ (IFNγ)) are observed in patient samples ex vivo 47 . Adoptive transfer of in vitro-derived T H 9 cells shows IL-9-dependent effector function in allergic lung inflammation 10, 13, 24 . Thus, there is considerable evidence for the in vivo stability of the T H 9 cell phenotype and it is possible that the inability to examine the stability of the T H 9 cell subset in vitro is a result of the technical limitations of current culture systems.
pulmonary atopic disease models, they have a distinct role in atopic disease development from that of T H 2 cell immune responses and they are sufficient to generate allergic inflammation in transfer models.
T H 9 cells in IBD.
Crohn disease and ulcerative colitis are the principal forms of inflammatory bowel disease (IBD), which is defined as a chronic relapsing inflammation of the gastrointestinal tract that is independent of specific pathogen infection. Patients with Crohn disease show a pronounced T H 1-type immune response (associated with IFNγ and TNF production), whereas patients with ulcerative colitis have elevated levels of T H 2 cell-derived cytokines. + T cells within the gastrointestinal tract compared with control patients or patients in remission [69] [70] [71] . Interestingly, IL-9 production by these cells was only observed in patients with ulcerative colitis, and there was an association of IL9 expression and IL-9 + T cells with the severity of pathology 69, 71 . In mouse models of IBD, the co-transfer of CD4 + CD45RB
hi T cells and in vitro-derived T H 9 cells into recombination-activating gene (RAG)-deficient hosts resulted in increased development of colitis compared with control animals receiving CD4 + CD45RB hi T cells alone 7 , through a mechanism that was dependent on IL-9 (REF. 69 ). In an oxazolone-induced colitis model 72, 73 , IRF4-deficient and IL-9-deficient mice had significantly reduced colitis scores 69, 74 . The effect of IRF4 deficiency on colitis is at least partially due to reduced T H 17 cell responses 70 . However, the fact that attenuated colitis is seen in mice that lack PU.1 expression in T cells indicates that T H 9 cells are also important in the development of colitis 69 . In these experiments, the ability of T H 9 cells to mediate colitis was shown to be IL-9 dependent, as IL-9-deficient T cells and IL-9 neutralization attenuated colitis 69 . IL-9R expression is also elevated in gastrointestinal epithelial cells in patients with ulcerative colitis 69, 71 . Treatment of Caco-2 cells, which are a human epithelial cell line, with IL-9 was shown to inhibit cellular proliferation 71 . Gerlach et al. 69 not only substantiated the negative effect of IL-9 on epithelial cell proliferation but also noted that topical administration of recombinant IL-9 attenuated epithelial cell tissue repair mechanisms in vivo. Furthermore, IL-9 increased intestinal permeability, which may be a result of IL-9 altering tight junction protein composition in the gastrointestinal epithelial cell layer 69 . Collectively, these results indicate that T H 9 cells and IL-9 directly alter epithelial cell biology within the gastro intestinal tract, potentially contributing to the pathology of IBD. Whether T H 9 cells contribute to colitis mainly through effects on epithelial cells or through effects
Box 3 | Interleukin-9: sources and functions
Although this Review focuses on T helper 9 (T H 9) cells, there are other sources of interleukin-9 (IL-9) within the immune system (see the figure) . Type 2 innate lymphoid cells (ILC2s) potently produce IL-9 in mice challenged with papain and helminthic parasites, as well as following in vitro stimulation with IL-2 (REFS 54,61). Mast cells also produce IL-9 in response to Toll-like receptor (TLR) and cytokine signals [112] [113] [114] . CD8 + T cells can acquire an IL-9-producing phenotype, and these cells have been referred to as 'T C 9' cells 115, 116 . Natural killer T (NKT) cells express IL-9 in models of allergic and autoimmune inflammation 76, 117 . Other CD4 + T cells -including T H 2, T H 17 and regulatory T (T Reg ) cells -have been reported to produce IL-9, although the amounts of IL-9 produced by each of these cell types is generally less than that produced by a T H 9 cell 20, 80, 118 . Further work is needed to fully define the levels of IL-9 that are produced by these cell types and the contribution of each cell type during various immune responses. IL-9, similarly to many cytokines, is pleiotropic in function. On haematopoietic cells, IL-9 signals through a specific IL-9 receptor chain (IL-9Rα) and the common γ-chain (γc; also known as IL-2Rγ), which is shared with the receptors for related cytokines including IL-2, IL-4 and IL-21 (REFS 119, 120) . IL-9 promotes mast cell and T cell growth, stimulates mast cell accumulation in tissues, promotes ILC survival, enhances class-switching to IgE in B cells and alters haematopoietic progenitor cell activity 4, 5, 64 . Although some in vivo IL-9 functions require T H 2-type cytokine production, IL-9 can promote the differentiation of IL-17-secreting cells in vitro 24, 67, 81 . IL-9Rα is also expressed on non-haematopoietic cells, including on airway and intestinal epithelial cells, smooth muscle cells and keratinocytes 4, 5 . If there are additional signalling requirements for IL-9 function in non-haematopoietic cells, they have not yet been defined. IL-9 stimulates chemokine production from all of these cell types, enhances mucus production from airway epithelial cells and alters barrier function in the intestines 4, 5, 69 . Thus, IL-9 is instrumental in the ability of many cells to regulate inflammation and immunity by affecting many cell types. Nature Reviews | Immunology on the immune system is not clear. However, some effects of IL-9 on epithelial cells may be indirect, as suggested by mast cell-dependent effects in a model of antigen-induced anaphylaxis 75 .
It is interesting to note that, IL-9 attenuates disease development 76 in a T H 1 cell-mediated colitis model that shares some of the hallmarks of Crohn disease 73 . The role of T H 9 cells in this disease model remains to Figure 3 | T H 9 cells in immunity and disease. Proposed effector activities of T helper 9 (T H 9) cells in human disease are shown. a | The number of T H 9 cells present in the draining lymph nodes and the airways strongly correlates with asthmatic disease. T H 9 cell-derived interleukin-9 (IL-9) can exacerbate the immune response by enhancing antibody production and by increasing immune cell infiltration and activity within the respiratory tract. Furthermore, IL-9 can increase collagen deposition, induce smooth muscle hyperplasia and alter respiratory epithelial cell function. b | T H 9 cells have been implicated in contributing to inflammatory bowel disease (IBD), particularly ulcerative colitis. T H 9 cells, through IL-9 production, can impair tissue repair processes, can increase intestinal permeability and may enhance pro-inflammatory T H cell responses. c | T H 9 cells can have potent antihelminth activity against certain parasites as a result of the production of IL-9. IL-9 mediates antiparasitic activity by altering epithelial cell function, by increasing immune cell infiltration into infected locations and by augmenting leukocyte function. Although NKT cell-derived IL-9 production seems to be limited in patients with ulcerative colitis 71 , it may be that the role of IL-9, and of T H 9 cells themselves, can be protective or inflammatory in the gastrointestinal tract depending on the inflammatory milieu.
T H 9 cells in EAE. EAE is an experimental animal model of multiple sclerosis that is characterized by T cell-dependent demyelination. EAE is associated with T H 1 cell and T H 17 cell responses, and T H 17 cells have been identified in the central nervous system (CNS) of patients with multiple sclerosis 77 . T H 9 cells are present in the draining lymph nodes and CNS of mice administered myelin proteo lipid protein peptide PLP [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] to induce EAE 52 , and the adoptive transfer of myelin oligodendrocyte glycoprotein (MOG)-specific T cells cultured under T H 9 cell-inducing conditions into RAG-deficient mice promoted EAE 23, 30, 78 .
Although T H 9 cell-mediated EAE is not as severe as the EAE induced by T H 17 cells 78 , adoptive transfer of T H 9 cells can trigger peripheral neuropathy that is not as apparent in recipients of T H 1 cells or T H 17 cells 7, 78 . T H 9 cell-mediated EAE is dependent on IL-9 (REF. 30 ), which has a well-documented role in EAE pathogenesis because of its ability to enhance T H 1 cell and T H 17 cell immune responses during disease progression 37, 79, 80 . By contrast, other studies have suggested that IL-9 can also have a protective effect before the induction of EAE, possibly by enhancing T Reg cell activity 37, 81 . Further complicating the interpretation of these studies, subsequent to adoptive transfer in an EAE model, many T H 9 cells acquire the ability to produce IFNγ and IL-17 (REFS 23, 78) , and the acquisition of IFNγ production partly promotes EAE severity 23 . This parallels observations from a model of autoimmune uveitis 82 . Furthermore, it is unclear in non-adoptive T cell transfer models whether the cellular source of IL-9 is T H 9 cells or another cell type such as T H 17 cells 80 . Further use of non-adoptive transfer models will be required to validate the role of T H 9 cells in EAE and to ultimately define their role in multiple sclerosis.
T H 9 cells in helminth infections. Parasitic helminth infections affect more than 1 billion people worldwide, and T H cells have been documented to exacerbate or to limit pathology 83, 84 . Circulating antigen-specific T H 9 cells have been detected in individuals with lymphatic filariasis, which is a chronic helminth infection 85 . In a Trichuris muris infection model, mice with a CD4 + T cell-restricted deficiency of TGFβ receptor type 2 (TGFβR2) have reduced IL-9 levels, decreased mast cell numbers and a significantly increased worm burden compared with controls, which indicates that T H 9 cells may be important in immunity to helminths 6 . T H 9 cells, but not T H 2 cells, were able to reduce Nippostrongylus brasiliensis worm burdens upon adoptive transfer into RAG-deficient hosts 61 . In this model, T H 9 cell transfer enhanced numbers of infiltrating eosinophils, basophils and mast cells. Furthermore, T H 9 cells increased ILC2 numbers and activity 61 , which may be due to the effect of IL-9 in promoting ILC2 survival in vivo 54, 64 .
In the current paradigm, T H 9 cells mediate antihelminth immunity though the local or systemic production of IL-9. During T. muris and N. brasiliensis infections, IL-9 is required for worm expulsion 61, 62, 86 and transgenic expression of the cytokine enhances resistance to T. muris infections 87 . During Trichinella spiralis infection, IL-9 facilitates, but is not essential, for overall worm expulsion. In this model, IL-9 modulates intestinal muscle contraction and epithelial cell mucus production, as well as mast cell activity, which, in particular, is required for IL-9-mediated worm expulsion 86, 88, 89 . The relative contributions of T H 9 cells and ILC2s to systemic IL-9 production in helminth infections are still not clear. In IL-9 fate reporter mice with pulmonary N. brasiliensis infection, IL-9 was shown to be derived from ILC2s that were previously shown to be a source of IL-9 in a T cell-independent asthma model 54, 64 . By contrast, using transcriptional reporter mice, LiconaLimon et al. 61 noted that CD4 + T cells were the principal producers of IL-9 within the gastrointestinal tract in a similar N. brasiliensis infection model. Furthermore, transfer of T H 9 cells into Il9 −/− mice rescued any defect associated with worm expulsion. Thus, T H 9 cells are probably a major source of protective IL-9 in certain helminth infections. However, IL-9 may not be essential for protection in all helminth infections and may even be detrimental for host health as parasite-specific T H 9 cell numbers positively correlated with disease severity in individuals suffering with lymphatic filariasis 85 . T H 9 cells in tumour immunity. An intriguing function of T H 9 cells is their highly potent antitumour activity, particularly in melanoma. Numbers of T H 9 cells in the blood and the skin are significantly reduced in patients with melanoma compared with in healthy individuals 90 , and an IL9 single nucleotide polymorphism (SNP) is associated with an increased risk of cutaneous malignant melanoma 91 . In the B16-F10 melanoma models, several laboratories have shown that adoptive transfer of T H 9 cells markedly reduces tumour masses and disease severity compared with controls 32, 90, 92 . Through the administration of neutralizing antibody or recombinant protein, researchers have shown that IL-9 has potent antitumour effects in a mouse model of melanoma. Furthermore, T H 9 cells and IL-9 are protective in a lung adenocarcinoma model 32, 90 , which indicates that T H 9 cells may have antitumour properties in several tissues.
Although there are conflicting reports indicating that T H 9 cells can directly induce tumour cell death 90, 92 , the ability of T H 9 cells to limit tumour growth seems to be mainly dependent on the production of cytokines -including IL-3, IL-9 and IL-21 -to enhance developing and existing tumour immunity. IL-9 can induce the expression of CC-chemokine ligand 20 (CCL20) within the tumour site and CC-chemokine receptor 6 (CCR6) expression on leukocytes to facilitate tumour infiltration and rejection 92 . Furthermore, IL-9 antitumour activity is mast cell dependent 90 . T H 9 cells are also potent producers of IL-3 following TCR stimulation 10 . T H 9 cell-derived IL-3 has been shown to promote DC survival, which could potentially enhance antitumour immunity 93 . Végran et al. 32 recently showed that IL-21 derived from T H 9 cells inhibited tumour growth even in the absence of IL-9 production. In an in vitro setting, T H 9 cells can produce amounts of IL-21 that are comparable to T H 17 cells following TCR stimulation 10, 94 , and Végran et al. 32 showed that IL-1β enhances T H 9 cell production of IL-21 to inhibit tumour growth, partly by enhancing CD8 + T cell responses and IFNγ production. As IL-1β might also increase IL-9 production 31, 32, 59, 95, 96 , the anti tumour microenvironment might further amplify T H 9 cell immune responses and thus antitumour immunity.
The protective effects of T H 9 cells in tumour immunity might be restricted to solid tumours, such as melanoma and lung adenocarcinoma. IL-9 has been linked with the promotion of certain cancers, particularly lymphomas. IL9 is strongly expressed in a subset of patients with anaplastic lymphoma and Hodgkin disease 97 . Transgenic Il9 expression promotes the development of spontaneous lymphomas in mice, and in a T lymphoblastic lymphoma mouse model, IL-9 can enhance tumour development 98 . In vitro studies indicate that IL-9 promotes tumour growth by both enhancing proliferation and inhibiting apoptosis of tumour cells 99, 100 . It is unclear whether T H 9 cells are a relevant source of IL-9 during lymphoma development but it may indicate that T H 9 cells can be both pro-tumorigenic and antitumorigenic depending on the cancer type. The basis for IL-9, and potentially T H 9 cells, to have discriminatory effects on different cancers is unexplored but could be linked to the differential expression of IL-9R on the cancer cell type.
Concluding remarks
Signals from TGFβ and IL-4 promote T H 9 cell differentiation, but neither cytokine is sufficient by itself to generate the T H 9 cell transcriptional profile or to induce high amounts of IL-9 expression in T cells 10 . Among the transcription factors that respond to these cytokine signals, none can be regarded as 'master regulators' in the same way that T-bet, GATA3 or FOXP3 can be associated with their respective T H cell lineages. However, it is still possible that there is an unidentified T H 9 cell lineagedefining transcription factor. Another possibility is that these cytokine signals work cooperatively in promoting IL9 gene expression. The TGFβ-induced SMADs and PU.1 remodel chromatin and might function to allow the IL-4-induced transcription factors BATF and IRF4 to transactivate gene expression. As noted in the description above, there is cooperation at the level of inducing transcription, and factors activated by both signals are probably crucial in recruiting RNA polymerase to target loci to cooperate in generating the phenotype and function of the T H 9 cell subset.
Our understanding of the biology of T H 9 cells is rapidly developing in multiple human diseases and mouse disease models. It is becoming clear that, as is the case with many other T H cell subsets, T H 9 cells can have both beneficial and detrimental functions in the body. Where they mediate these effects is not entirely clear, but some emerging paradigms suggest that T H 9 cells are found in the skin and that they express receptors that would facilitate their recruitment to mucosal surfaces 10, 48, 52, 90 . Among the beneficial effects T H 9 cells mediate is their ability to initiate immunity to helminth parasites and effective antitumour immunity. By contrast, T H 9 cells promote allergic inflammation and mediate some types of autoimmunity. These functions raise the questions of the instances in which T H 9 cell-targeted or IL-9-targeted therapies might be useful. MEDI-528 (also known as enokizumab), which is a humanized IL-9-neutralizing antibody, has an acceptable safety profile and shows some promise in minimizing exacerbations in adult patients with mild to moderate asthma 101, 102 , although no positive effects were noted in adults with severe asthma 103 . The discrepancy in the effects of treatment might be in the subtypes of asthma studied; it is possible that the group with mild to moderate asthma had disease that might be more dependent on the function of IL-9, such as a requirement for mast cells in disease exacerbations. Targeting IL-9 in other allergic diseases has not been reported. As increased IL-9 levels are seen early in life in an atopic population of infants and increases are associated with early changes in airway responsiveness 24, 104 , an acceptable safety profile might provide a basis for early intervention in high-risk infants to limit the development of atopic diseases. The recent descriptions of T H 9 cells in IBD suggest that targeting IL-9 might be a potential treatment in this disease. Thus, even in our infancy of understanding their development and function, T H 9 cells are revealed to be important mediators in multiple diseases, and the cells and the cytokines they produce remain intriguing targets for therapy.
